MECHANISM OF ACTION OF THROMBIN ON PLATELETS
(Submitted for publication September 8, 1961 ; accepted October 9, 1961) Thrombin, a proteolytic enzyme, is known to initiate certain reactions of platelets including aggregation (1), retraction of clots (2) , and release of serotonin (3) . Thrombin aggregates platelets in hypofibrinogenemic (4) or normal citrated (5) or oxalated (6) plasma, in prothrombin-poor serum (7) , in buffer at pH 7.3 to 7.6 (6) , and in saline containing albumin (6) or a number of compounds of low molecular weight (8) . Fibrinogen,' a recognized substrate of thrombin, has been demonstrated in extracts of platelets (9) . The present studies define some of the conditions under which platelets react with thrombin. In particular, the role of fibrinogen in these reactions was investigated.
MATERIALS AND METHODS
Glassware with which platelets had contact was coated with silicone.2 Venous blood was obtained from human donors either through 15-gauge needles attached to plastic tubing or through 18-gauge needles attached to syringes. Blood was collected without anticoagulant (native blood) or was mixed with 0.1 vol of a 2 per cent solution of the disodium salt of EDTA, 0.1 vol of 3.8 per cent sodium citrate solution, or 0.20 vol of acidcitrate-dextrose (ACD) solution (NIH formula A).
Platelet-rich plasma was prepared by centrifugation of blood at approximately 50 G for 30 minutes at room temperature. Platelet-free plasma was obtained by centrifugation of blood or platelet-rich plasma at 22,000 G for 10 minutes at 40 C. Platelet suspensions were prepared by centrifugation of platelet-rich plasma at approximately 4,700 G for 5 minutes at 4°C, and resus- 1 The term fibrinogen, as used in this presentation, refers to a protein substance that clots upon the addition of thrombin.
2General Electric silicone SC-87, Dri-Film. pension of the sedimented platelets in a volume of buffered saline approximately one-fifth of the volume of plasma. Buffered saline consisted of equal volumes of 3.6 per cent (0.3 M) Tris solution and 0.9 per cent sodium chloride solution, the pH adjusted to 7.5 with 2 N hydrochloric acid.
Trypsinized platelets were prepared by adding 0.20 vol of trypsin in buffered saline to suspension of platelets obtained from platelet-rich plasma containing EDTA. The final concentration per ml of platelet suspension was 1,000 ug of a preparation containing trypsin and magnesium sulfate, or 50 lsg of salt-free trypsin 4 . Suspensions were incubated at 370 C for 10 minutes. After centrifugation at 4,700 G for 5 minutes at 40 C, sedimented platelets were suspended in about twice the volume of buffered saline containing EDTA (prepared by adding 1.0 ml of a 4.8 per cent solution of EDTA to 100 ml of buffered saline). The centrifugation was repeated, and platelets were resuspended in a volume equal to the original volume of platelet suspension, with the use of buffered saline, normal serum, or platelet-free plasma. Trypsinized platelets were used within 3 hours after the second washing.
Clottable protein from platelets (platelet fibrinogen) was obtained by a modification of the procedure of Ware, Fahey and Seegers (9) . Platelet-rich plasma was prepared from 1,000 ml of normal blood or from 150 to 200 ml of blood from each of 3 patients with thrombocytosis. A diagnosis of polycythemia vera had been made in two of the patients, and the third had myelofibrosis and myeloid metaplasia. The anticoagulant used was either EDTA or ACD solution. Plateletrich plasma was centrifuged at 1,500 G for 15 minutes at room temperature, and sedimented platelets were suspended in approximately 16.0 ml of buffered saline. The platelet suspension was divided into two equal parts, one of which was incubated at 37°C for 10 minutes with 0.20 vol of trypsin in buffered saline, and the other was incubated with buffered saline alone. The platelets were washed twice and suspended in approximately 2.0 ml of buffered saline. These suspensions were frozen and thawed five times in an alcohol-dry ice mixture and centrifuged at 22,000 G for 10 minutes at 40 C to remove platelet debris. Aliquots of the supernatant fluids were tested for clottable protein by addition of 0.20 vol of a solution of bovine thrombin (1,000 U per ml) in saline.
Aggregation of platelets by thrombin was evaluated after adding 0.20 vol of a solution of thrombin to platelets suspended either in buffered saline or in serum. Except where specified, a preparation of bovine thrombin5 was used in a final concentration of 200 NIH U per ml. Highly purified bovine thrombin or human thrombin 6 was employed in certain experiments that will be described. After mixing, the suspensions were incubated without agitation in Addition of thrombin alone resulted in macroscopic aggregation of the platelets followed by coagulation of the plasma. As the amount of thrombin was decreased, the time of appearance of platelet aggregation remained relatively constant, although the clotting time of the plasma became markedly prolonged (Table II) .
2. Aggregation of platelets in plasma by thrombin in the presence of heparin. Citrated platelet- 3. Recovery of platelets in serum or unclotted plasma after addition of thrombin. Platelet-rich plasma was prepared from normal donors, and thrombin alone or a mixture of thrombin and calcium chloride was added. The mixtures were incubated at 370 C for 30 minutes. Unretracting clots were twirled onto wooden applicator sticks until the serum was expressed, and the clots were discarded. Retracted clots were removed without manipulation. Platelet-counts were performed on unclotted plasma and on serum expressed from clots.
Results of studies in which thrombin alone was added to EDTA platelet-rich plasma are shown in Table IV . Firm clotting of plasma occurred with 2.5 U or more of thrombin per ml. No retraction occurred in any of the tubes because of the absence of free divalent cation. The number of morphologically intact platelets in serum or unclotted plasma was inversely related to the concentration of thrombin.
When thrombin and calcium chloride were added to EDTA platelet-rich plasma (Table IV) , firm clotting occurred with 1 or more U of thrombin per ml, and clots retracted with the higher thrombin concentrations. Visible clotting did not occur with low concentrations of thrombin (< 0.1 U per ml). The number of platelets in serum or unclotted plasma was inversely related to the concentration of thrombin. On microscopic examination these platelets appeared similar to those in untreated EDTA platelet-rich plasma. The platelet yield was higher when EDTA platelet-rich plasma was clotted with thrombin alone than with comparable amounts of thrombin in the presence of calcium.
In a similar experiment thrombin alone was added to citrated platelet-rich plasma. The number of platelets in serum or unclotted plasma again was inversely related to the concentration of thrombin.
The number of platelets recovered after addition of thrombin was examined in relation to plasma concentration. EDTA platelet-free plasma was diluted with various proportions of buffered saline. Platelets were added to the diluted plasma to a final concentration of 150,000 per mm3, and coagulation was induced by 0.20 vol of a solution 545 
Platelets obtained by lysis of clots with trypsin were as effective as fresh washed platelets in accelerating the coagulation time of recalcified plasma (Table V) .
Platelets released by lysis of unretracted and retracted clots were washed once in buffered saline containing EDTA and resuspended in platelet-free plasma in a concentration of approximately 150,000 per mm3. The plasma was then clotted by addition of 0.33 vol of a solution of calcium chloride and thrombin. In each of four experiments with trypsin, complete retraction occurred with platelets obtained by lysis of unretracted clots. In three of four experiments complete retraction was produced by platelets released by trypsin from retracted clots. In these experiments clots formed by the addition of thrombin alone did not retract since calcium was not available; there was no detectable lysis of these clots during a period of observation of 12 hours, indicating absence of residual tryptic activity. Platelets obtained by lysis of clots with streptokinase were similarly tested for their ability to * TP = trypsinized platelets; NTP = nontrypsinized platelets. Substrate consisted of 0.4 ml platelet suspension (715,000 platelets per mm3) to which was added a 0.1 ml solution of thrombin in buffered saline or in calcium chloride (0.025 M). Final concentration of thrombin was 0.5 U per ml.
produced by human thrombin in concentrations ranging between 1.0 and 100 U per ml. These preparations of thrombin did not aggregate washed platelets suspended in buffered saline, nor was aggregation produced by calcium chloride solution alone. Trypsinized platelets remained homogeneously dispersed in serum containing purified bovine or human thrombin.
In the experiments described above, platelets had been incubated with 1,000 ug of trypsin with magnesium sulfate, or 50 /Ag of salt-free trypsin per ml of platelet suspension. Platelets pretreated with lesser amounts of salt-free trypsin (0.1 to 1.0 Mtg per ml of platelet suspension), washed twice, and suspended in normal serum were aggregated by addition of thrombin.
Serum was prepared from a patient with classic hemophilia (antihemophilic factor or factor VIII deficiency) by incubating 5.0 ml of the patient's blood in uncoated glass tubes at 370 C for 2 hours. The serum contained > 50 per cent residual prothrombin. Trypsinized platelets were not aggregated on incubation in this serum, whereas nontrypsinized platelets were markedly clumped. Similar results were obtained when trypsinized and nontrypsinized platelets were incubated with normal serum that contained > 50 per cent residual prothrombin (prepared by incubating 2.0 ml native platelet-free plasma in uncoated glass tubes at 370 for 2 hours).
Aggregation of trypsinized and nontrypsinized platelets that were resuspended in EDTA plateletfree plasma was studied in four experiments. Results were similar, and data of one experiment are shown in (Figure 1 ).
In the experiments described above, platelets had been incubated with 50 ug of salt-free trypsin per ml of platelet suspension. The ability of platelets to induce retraction was abolished by pretreatment with high concentrations of trypsin (1,000 jug of salt-free trypsin per ml of platelet suspension). 4. Morphologic appearance of platelets in sections of clots. Changes that occurred in association with clotting and retraction were studied by microscopic examination of fixed and sectioned clots. Photomicrographs (Figure 2 ) are of sections of clots formed after addition of thrombin to trypsinized or nontrypsinized platelets suspended in a buffered solution of fibrinogen, calcium chloride, and glucose. Platelets showed swelling, irregularity, and some aggregation in clots fixed 1 minute after addition of thrombin and before the onset of visible retraction. In clots fixed 1 hour after addition of thrombin and after maximal retraction had occurred, platelets showed marked swelling and aggregation. Similar observations were made on clots formed by addition of thrombin and calcium chloride solution to EDTA plasma. The morphologic changes observed in clots containing trypsinized platelets were indistinguishable from those in clots containing nontrypsinized platelets.
5. Reactions of platelets with heterologous antiserum. Platelets suspended in buffered saline were mixed with various dilutions of a potent rabbit antihuman platelet serum. The titer of serum that caused agglutination of platelets was the same with trypsinized as with nontrypsinized platelets (Table VII) . (5, (15) (16) (17) . The present experiments demonstrate that macroscopically visible aggregation of platelets preceded fibrin formation when the process of coagulation was slowed by addition of small amounts of thrombin to citrated plateletrich plasma or by addition of calcium and small amounts of thrombin to EDTA platelet-rich plasma. It was possible to produce gross aggregation of platelets by thrombin in the absence of detectable clotting with the use of appropriate concentrations of heparin in citrated platelet-rich plasma. This observation suggests that lower concentrations of thrombin are effective in producing platelet aggregation than are required for the clotting of fibrinogen in plasma. Results obtained with EDTA platelet-rich plasma indicate that free divalent cations are necessary for the production of platelet aggregation by thrombin.
When coagulation occurs, platelets undergo a series of morphologic changes known as "viscous metamorphosis" (18, 19) , a phenomenon which is associated with aggregation and apparent fusion of the platelets and with retraction of the clot (11, 20) . These changes do not occur in the absence of available calcium or magnesium even though the platelets are embedded in fibrin clots formed by thrombin (11, 21) . In a study of fixed and sectioned plasma clots, platelets remained discrete and unaggregated when free divalent cation was not available (11) . The addition of calcium to such clots 2 hours after coagulation caused retraction of the clots (22, 23) . These morphologic observations are in accord with the data of other investigators (20, 24) , and with the results of the current studies, indicating that platelet aggregation, viscous metamorphosis, and clot retraction are closely related phenomena, initiated by the action of thrombin on platelets and requiring the presence of divalent cation.
Clot retraction is produced only by intact, biologically active platelets (25) . Large numbers of morphologically normal and functionally active platelets were recovered by lysis of unretracted clots which had been formed in the absence of free divalent cation. Clot formation per se clearly did not destroy or obviously damage platelets. More surprising was the recovery of a smaller proportion of intact platelets by lysis of completely retracted plasma clots which had been formed by thrombin in the presence of calcium. Obviously these platelets did not undergo the progressive and irreversible changes usually associated with coagulation and retraction. That they were capable of doing so was demonstrated by their ability to produce retraction of a clot subsequently formed. The number of platelets recovered from clots varied inversely with the concentration of thrombin employed to induce coagulation. Czernobilsky and Alexander (26) have previously observed that serum expressed from clots formed by recalcification may contain platelets capable of producing clot retraction.
Platelets have been shown to contain a clottable protein similar to or identical with fibrinogen (9, (27) (28) (29) . Previous investigators have debated whether platelet fibrinogen was present in the interior (30) or on the surface (28) of platelets. In the present experiments fibrinogen was not removed by repeated washing of platelets but was no longer detectable after platelets had been exposed to trypsin. Our observations favor the view that platelet fibrinogen is on the surface of platelets, since it is unlikely that trypsin could have removed or altered fibrinogen within the platelets without disrupting them. Hjort, Rapaport and Owren (31) have shown that the factor V activity of platelets can similarly be removed by trypsin.
The present experiments indicate that at least some of the effects of thrombin on platelets are mediated by fibrinogen. Washed platelets suspended in fibrinogen-free serum were grossly aggregated by thrombin, whereas platelets previously exposed to trypsin remained freely dispersed under the same conditions. Presumably the fibrinogen on the surface of the platelets was the substrate of thrombin in the production of platelet aggregation. Trypsinized platelets resuspended in a solution containing fibrinogen regained their ability to be aggregated by thrombin.
When potent preparations of thrombin were mixed with a suspension of washed platelets in serum there was pronounced clumping of the platelets, but the platelets were not destroyed.
The platelets in these clumps, when resuspended in a medium containing fibrinogen, did produce clot retraction after clotting was induced by thrombin. Thus the degree of reaction of platelets to thrombin was apparently related to the amount of fibrinogen available. Since it was necessary to add only purified fibrinogen to achieve this effect, the result must be attributable to fibrinogen alone or, conceivably, to a contaminant of the fibrinogen preparation. The latter seems unlikely, since aggregation of trypsinized platelets did not occur in whole fresh serum.
Platelets not only remained intact morphologically after incubation with trypsin but also retained their ability to support retraction of clots formed from a buffered solution of purified fibrinogen containing calcium and glucose. Sections of these clots showed that the changes of trypsinized platelets occurring during clotting and retraction were similar to those of nontrypsinized platelets. Although thrombin was apparently essential to initiate the alterations leading to viscous metamorphosis and clot retraction, the continued presence of thrombin was apparently not required for these reactions. Nonretracting clots formed by addition of thrombin to prothrombin-free EDTA plasma proceeded to retract when calcium was added more than 4 hours after clot formation, at a time when thrombin presumably had been inactivated (23) . In this experiment fibrinogen solution was added at the same time as the calcium and did not clot, indicating the absence of detectable thrombic activity. These observations suggest that divalent cation, essential for clot retraction, exerts its effect at a stage later than the action of thrombin.
We conclude that fibrinogen on the surface of platelets is the substrate of thrombin in the production of platelet aggregation, viscous metamorphosis, and clot retraction. Additional experiments are in progress to determine whether fibrinogen is involved in the release of serotonin from platelets by thrombin. A relationship betwveen fibrinogen and aggregation of platelets has been postulated by others. Lenggenhager (32) suggested that platelets might adsorb freshly formed fibrin and thus become viscous and aggregate, and Apitz (33) proposed that profibrin, an intermediate product of the conversion of fibrinogen to fibrin, might be adsorbed by platelets and produce platelet aggregation. In recent years, however, the concept of an interaction of thrombin and fibrinogen as a cause of viscous metamorphosis has been in disfavor mainly as a result of reports that viscous metamorphosis occurs in platelets from patients with congenital fibrinogen deficiency. Pinniger and Prunty (34) and Alex- ander and co-workers (4) showed that the platelets from such patients did undergo viscous metamorphosis when blood was exposed to glass surfaces, even though clotting did not occur. Vandenbroucke, Verstraete and Verwilghen (35) reported "pouvoir d'agglutination" of the platelets from a patient with congenital afibrinogenemia, thought on subsequent studies to have no fibrinogen on the platelets (36) . However, Alexander and colleagues (4) and Setna and Rosenthal (5) described small strands resembling fibrin associated with platelets undergoing viscous metamorphosis in the blood of patients with congenital hypofibrinogenemia.
Agents possibly related to coagulation factors but other than thrombin have reportedly caused aggregation of platelets. Some of these agents include serum (19) , serum rich in prothrombin (7, 37) , "factor R" of Hellem (38) released from red blood cells, "product I" of Bergsagel (39), a "thrombocyte agglutinating factor" of Brinkhous and co-workers (40) , EDTA plasma to which divalent cation was added (41) , and an "interaction of Hageman or tissue factor with PTA or plasma platelet factor" (17) . Some of the agents mentioned have been shown to contain thrombin or to produce it during their interaction with platelets (7); and in the present studies, serum containing a high concentration of prothrombin produced aggregation of nontrypsinized but not of trypsinized platelets. If there are substances in normal serum other than thrombin that cause platelet aggregation, these substances apparently do not react with trypsinized platelets. Certain chemical and other foreign agents seemingly unrelated to coagulation also can produce platelet aggregation (42, 43) . In our experiments trypsinized platelets retained their ability to react with rabbit-antihuman platelet serum. Antiplatelet serum has been shown to contain several antibodies acting on platelets, including an antifibrinogen antibody (44) . Our results suggest that the antifibrinogen effect of antiplatelet 551 serum is less than the antiplatelet effect, since removal of platelet fibrinogen by trypsin did not affect the titer. Miescher and Gorstein (45), using different techniques, have come to similar conclusions.
SUM MARY
Thrombin added to platelet-rich plasma produced platelet aggregation prior to clotting of the plasma provided free divalent cation was present. Addition of appropriate amounts of thrombin to citrated platelet-rich plasma containing small amounts of heparin produced platelet aggregation even though coagulation of the plasma never occurred.
The number of morphologically intact platelets recovered after addition of thrombin to plateletrich plasma was inversely related to the concentration of thrombin. A large number (> 70 per cent) of morphologically intact and functionally active platelets was recovered after lysis of nonretracted clots formed in the absence of free divalent cation. A smaller number of intact platelets was recovered after lysis of retracted clots formed in the presence of free divalent cation.
Platelets incubated with trypsin remained morphologically intact. Nontrypsinized platelets in normal serum were aggregated by thrombin. Trypsinized platelets in normal serum were not aggregated by thrombin. Trypsinized platelets supported retraction of clots formed from either plasma or purified fibrinogen. The histologic changes associated with clotting and retraction were similar with trypsinized and nontrypsinized platelets. Extracts of nontrypsinized platelets contained thrombin-clottable protein (platelet fibrinogen). Extracts of trypsinized platelets did not contain platelet fibrinogen. These results suggest that the substrate for the action of thrombin in the production of platelet aggregation and clot retraction is a protein clottable by thrombin similar to or identical with fibrinogen, and situated on the surface of the platelets.
